BALTIMORE - TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) announced today that it is moving forward with fully funded mid-stage clinical trials for its lead drug, MYMD-1®, following promising Phase 2 study results. MYMD-1, a small molecule therapy, has been shown to regulate the immuno-metabolic system by inhibiting excess TNF-alpha activity, a protein associated with inflammation.
The recent Phase 2 clinical study of MYMD-1 targeted sarcopenia, a condition characterized by age-related muscle degeneration, which currently lacks FDA-approved treatments. The study achieved its primary goal, demonstrating a statistically significant reduction in chronic inflammatory markers. No adverse events related to the treatment were reported.
TNF Pharmaceuticals also holds FDA-approved Phase 2 Investigational New Drug (IND) applications for MYMD-1 to treat two other chronic inflammatory conditions, rheumatoid arthritis and Hashimoto’s thyroiditis. The company suggests that MYMD-1 has the potential to disrupt the TNF-alpha inhibitor market if approved. Dr. Mitchell Glass, President and Chief Medical Officer of TNF Pharmaceuticals, expressed optimism about the drug's future development and the company's growth.
In addition to MYMD-1, TNF Pharmaceuticals is developing a secondary drug platform, Supera-CBD™, a synthetic cannabidiol analog intended for treating epilepsy, pain, and anxiety/depression. Supera-CBD has shown potential for treating opioid addiction based on its interaction with opioid receptors.
TNF Pharmaceuticals focuses on extending healthy lifespans by developing therapies that address the causes of diseases marked by inflammation. The company's forward-looking statements reflect its intentions to continue advancing its pharmaceutical candidates, though they emphasize that actual results may differ due to various risks and uncertainties.
This news article is based on a press release statement from TNF Pharmaceuticals, Inc.
In other recent news, TNF Pharmaceuticals has adopted a new stock ticker symbol, "TNFA," coinciding with its rebranding from MyMD Pharmaceuticals. This change reflects the company's strategic focus on the development of treatments targeting TNF-alpha, a protein involved in inflammation and autoimmunity. Its lead clinical candidate, MYMD-1®, is designed to inhibit TNF-alpha, aiming to restore immune system regulation. The company's President, Chief Medical Officer, and Director, Mitchell Glass, stated that this rebranding marks a significant moment in the clinical development of MYMD-1®. Current stockholders are not required to take any action regarding the ticker symbol update, as all trading and market information will be reported under the new symbol. In addition to MYMD-1®, TNF Pharmaceuticals is also developing Supera-CBD, a synthetic derivative of cannabidiol (CBD), for the treatment of chronic pain, addiction, and epilepsy. These are some of the recent developments in the company.
InvestingPro Insights
As TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) progresses with clinical trials for its promising drug MYMD-1, investors are closely monitoring the company's financial metrics to assess its investment potential. According to recent data from InvestingPro, MYMD's Price to Earnings (P/E) Ratio stands at a negative 0.25, reflecting the company's current lack of profitability as it channels its resources into research and development. However, the PEG Ratio, which measures a stock's valuation while also factoring in future earnings growth, is at a more optimistic 0.05, suggesting that investors may be expecting growth as clinical trials continue.
Another key metric, the Price to Book (P/B) Ratio, is currently at 0.45, indicating that the stock is trading at a discount relative to its book value, which could attract value investors. Despite the challenges in the biotech industry, TNF Pharmaceuticals exhibits a strong commitment to innovation, as evidenced by a Price percentage of its 52-week high at just 2.91%, hinting at a potential upside if MYMD-1 achieves regulatory success.
While the company's Return on Assets (ROA) at -57.28% highlights the high-risk nature of investing in pharmaceuticals in the development stage, the InvestingPro Fair Value estimate of 1.66 for MYMD suggests that the stock may be undervalued at its current price, providing an opportunity for investors who believe in the long-term prospects of MYMD-1 and Supera-CBD™.
For those looking for more in-depth analysis, InvestingPro offers additional insights and tips on TNF Pharmaceuticals, with a current total of 15 InvestingPro Tips available to subscribers, providing a more comprehensive investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.